Cervical Lesion Articles & Analysis
6 news found
With that, DYSIS has been awarded with the 2021 Frost & Sullivan New Product Innovation Award — North American Smart Colposcopy for Cervical Lesion ...
Specifically, INOVIO's lead therapeutic candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. ...
Specifically, INOVIO's lead therapeutic candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. ...
VGX-3100 is in Phase 3 clinical trials to study the immunotherapy candidate for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL) and in Phase 2 clinical trials to study the immunotherapy candidate for the treatment of anal and vulvar HSIL. ...
It is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus (HPV-16 and HPV-18). "As we advance our DNA medicines platform, we are always looking for ways to drive innovation with our own technology or that of a creative and ...
Human papilloma virus (HPV) infection has been recognized as the necessary cause of cervical intraepithelial neoplasia (CIN1/2/3) and cervical cancer. HPV infection is the most common sexually transmitted disease, affecting about 400 million women worldwide. Persistent HPV infection can lead to CIN2/3 and then to cervical cancer. Worldwide, ...